Dr. Carrie Hersh, a neurologist at Cleveland Clinic, provided clinical insights on multiple sclerosis and autoimmune disorders during the 2024 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting [1].
These updates are critical for improving patient outcomes in chronic disease management. By integrating new technology and adherence strategies, clinicians aim to slow the progression of autoimmune disorders and enhance the quality of life for patients.
Hersh specializes in the treatment of multiple sclerosis and autoimmune disorders at the Cleveland Clinic in Ohio [1]. Her contributions to the meeting in Nashville, Tennessee, focused on advancing care through the sharing of clinical research and practical insights [1, 2].
One primary area of focus involved the application of artificial intelligence in the neurological field. Hersh said AI can be leveraged to improve diagnostic accuracy and personalize treatment plans for patients facing complex autoimmune challenges [1, 3].
Additionally, the discussions addressed the persistent challenge of medication adherence. Hersh said strategies are needed to ensure patients remain consistent with their prescriptions, which is a vital component in preventing relapses in multiple sclerosis patients [1, 3].
The 2024 meeting [1] served as a hub for researchers and practitioners to align on the latest evidence-based practices. By focusing on the intersection of technology and patient behavior, the CMSC aims to standardize a higher level of care across neurological clinics in the U.S. [1, 2].
Hersh said the goal of these efforts is to advance research and care for those living with MS and autoimmune disorders [1, 3].
“Dr. Carrie Hersh provided clinical insights on multiple sclerosis and autoimmune disorders.”
The integration of AI and a renewed focus on medication adherence represent a shift toward precision medicine in neurology. As clinicians like Dr. Hersh implement these strategies, the focus moves from general symptom management to highly personalized, data-driven interventions that could reduce long-term disability for MS patients.
